China NT Pharma Group Company Limited

Equities

1011

KYG2114L1059

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:20 2024-04-26 am EDT 5-day change 1st Jan Change
0.026 HKD +4.00% Intraday chart for China NT Pharma Group Company Limited +18.18% -52.73%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
China NT Pharma Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
China NT Pharma Group Company Limited Announces Directorate Changes CI
China NT Pharma Group Company Limited Announces Change of Company Secretary, Effective 31 December 2023 CI
China NT Pharma Group, Private Equity Fund Sign Cooperation Agreement; Shares Rise 4% MT
China NT Pharma Raises HK$13 Million from Private Placement MT
NT Pharma Seeks Nearly HK$24 Million from Share Placement MT
China NT Pharma Group Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
China NT Pharma Lays Out Restructuring Plan for Embattled Unit Suzhou First Pharma MT
China NT Pharma Unit Faces Lawsuits for Alleged Loan Default MT
China NT Pharma Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
China Nt Pharma Group Company Limited Announces Change of Independent Non-Executive Director and Member of Audit Committee CI
Konruns Pharma Cancels Osteoporosis Drug Agreement With NT Pharma, US-based Pfenex MT
China NT Pharma Group Company Limited Reports Earnings Results for the Half Year Ended June 30, 2022 CI
China NT Pharma Group Company Limited Announces Resignation of Wu Weizhong as Executive Director and Senior Vice President CI
China NT Pharma Signs Licensing Deal with US Company for Antibody Products MT
China NT Pharma Group Company Limited Intends to Set Up A Joint Venture Company CI
China NT Pharma Group Company Limited Updates on Delay in Publication of Audited Annual Results for the Year Ended 31 December 2021 CI
China NT Pharma Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2021 CI
China NT Pharma : Narrows H1 Loss on Increased Antipsychotic Drug Sales MT
China NT Pharma Group Company Limited Reports Earnings Results for the Half Year Ended June 30, 2021 CI
China NT Pharma : NT Pharma to Narrow Loss, Increase Revenue in H1 MT
China NT Pharma Group Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2021 CI
Fortune Blaze Investments Limited completed the acquisition of The Mountains Limited from China NT Pharma Group Company Limited. CI
China NT Pharma : Logs Lower Loss in 2020 as Revenue Soars 44% MT
China NT Pharma Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Chart China NT Pharma Group Company Limited
More charts
CHINA NT PHARMA GROUP COMPANY LIMITED is a China-based company principally engaged in the research and development, production and sales of pharmaceuticals. The Company mainly conducts its businesses through two segments. The Proprietary Product Production and Sales segment is engaged in the production and sales of NT branded products and generic drugs through its subsidiaries. The Miacalcic segment is engaged in the sales and marketing of miacalcic injectable and nasal spray branded products for treatment of bone pain caused by osteolysis and lower bone mass, as well as sub-licensing of intellectual property rights and distribution rights.
More about the company
  1. Stock Market
  2. Equities
  3. 1011 Stock
  4. News China NT Pharma Group Company Limited
  5. China NT Pharma : Board Urges Shareholders to Approve $10 Million Sale of Industrial Land